ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis.

These findings suggest a potential therapeutic benefit, although impact on clinical prognosis remains to be established. Targeting ITGB5 in CAFs may reduce the excessive stiffness of PDAC tissue and mitigate gemcitabine-associated stromal fibrosis, suggesting a potential strategy to improve treatment response.

The researchers measured cell number and viability in the study's cell samples with Countstar Rigel S2 before single-cell analysis in the 2025 Journal of translational medicine study.